Safety and effectiveness of an investigational insulin delivery device providing basal/bolus therapy with rapid-acting or regular human insulin in adults with type 2 diabetes.
This study undertook to assess usability, 24-hour glycemic profiles, and safety of an investigational basal/bolus insulin delivery device (IDD) providing rapid-acting or regular human insulin (RHI) for people with type 2 diabetes (T2D) transitioning from multiple daily insulin injections (MDI). This prospective, single-center, open-label, two-period study enrolled adults with T2D and HbA1c 7-11% (53-97 mmol/mol). Participants continued usual MDI therapy during a 2-3-day in-clinic MDI period and then within 7 days were switched to the IDD, using current insulin dose, for a 6-day in-clinic IDD period, with blinded continuous glucose monitoring throughout in-clinic periods. We enrolled 21 participants (mean±SD age 57±8 years; HbA1c 8.2±0.9% [66±9.8 mmol/mol]) using U-100 insulin lispro (n=11) or switched to U-100 RHI (n=10). Glycemic measures improved from the MDI to IDD period, including fasting blood glucose (BG), 141.2±38.3 mg/dl (7.8±2.1 mmol/L) vs. 121.2±35.0 mg/dl (6.7±1.9 mmol/L; P=0.002), respectively; 24-hour mean BG, 137.0±20.5 mg/dl (7.6±1.1 mmol/L) vs.125.0±16.5 mg/dl (6.9±0.9 mmol/L; P=0.004), and time-in-range (70-180 mg/dL; 3.9-10 mmol/L), 81.0±14.4% vs. 87.5±10.6% (P=0.008). No significant differences between MDI and IDD were recorded for time <70 mg/dL (1.6±2.7% vs. 3.1±2.7%, P=0.08), CV%, or mean of daily differences. Mean amplitude of glycemic excursions (MAGE) was significantly lower with the IDD (P=0.011). There were no significant differences between insulin lispro and RHI for any glycemic measure. No serious adverse events were recorded. In the context of this exploratory study, the IDD was safe and effective to administer insulin lispro and RHI for adults with T2D.